Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2023-12-12 Purchase | 2023-12-14 6:21 pm | Quince Therapeutics Inc. | QNCX | Lamond David Director | 67,881 | $1.0199 | $69,233 | 6,686,387 (Indirect Direct) | View |
| 2023-12-05 Purchase | 2023-12-07 6:30 pm | Quince Therapeutics Inc. | QNCX | Lamond David Director | 57,369 | $1.0133 | $58,134 | 4,316,215 (Indirect Direct) | View |
| 2023-11-29 Purchase | 2023-12-01 1:38 pm | Quince Therapeutics Inc. | QNCX | Lamond David Director | 43,134 | $0.94 | $40,546 | 4,258,846 (Indirect Direct) | View |
| 2023-08-30 Purchase | 2023-08-31 6:42 pm | Quince Therapeutics Inc. | QNCX | Lamond David Director | 82,052 | $1.315 | $107,898 | 4,215,712 (Indirect Direct) | View |
| 2023-08-15 Purchase | 2023-08-17 6:08 pm | Quince Therapeutics Inc. | QNCX | Lamond David Director | 250,000 | $1.3029 | $325,737 | 4,133,660 (Indirect Direct) | View |
| 2023-08-10 Purchase | 2023-08-11 4:15 pm | Quince Therapeutics Inc. | QNCX | Thye Dirk Chief Executive Officer | 88,000 | $1.26 | $110,880 | 448,911 (Direct) | View |
| 2023-08-08 Purchase | 2023-08-09 6:23 pm | Quince Therapeutics Inc. | QNCX | Thye Dirk Chief Executive Officer | 80,000 | $1.24 | $99,200 | 360,911 (Direct) | View |
| 2023-08-08 Purchase | 2023-08-09 6:21 pm | Quince Therapeutics Inc. | QNCX | Hannah Brendan Chief Business Officer | 71,762 | $1.22 | $87,550 | 201,555 (Direct) | View |
| 2023-08-08 Purchase | 2023-08-09 6:18 pm | Quince Therapeutics Inc. | QNCX | McLoughlin Margaret Director | 8,000 | $1.23 | $9,840 | 8,000 (Direct) | View |
| 2023-03-06 Sale | 2023-03-06 6:55 pm | Quince Therapeutics Inc. | QNCX | Monohon Ted Chief Accounting Officer & VP | 1,871 | $0.98 | $1,834 | 27,440 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-02-15 Option Award | 2024-02-15 6:14 pm | N/A 2034-02-15 | Quince Therapeutics Inc. | QNCX | Patni Rajiv Director | 54,000 | $0 | 54,000 (Direct) | View |
| 2024-02-01 Option Award | 2024-02-02 6:02 pm | N/A 2034-01-31 | Quince Therapeutics Inc. | QNCX | Ryan Charles S. PRESIDENT | 145,000 | $0 | 145,000 (Direct) | View |
| 2024-02-01 Option Award | 2024-02-02 5:53 pm | N/A 2034-01-31 | Quince Therapeutics Inc. | QNCX | Hannah Brendan CHIEF BUSINESS OFFICER AND COO | 600,000 | $0 | 600,000 (Direct) | View |
| 2024-02-01 Option Award | 2024-02-02 5:50 pm | N/A 2034-01-31 | Quince Therapeutics Inc. | QNCX | Thye Dirk CEO AND CHIEF MEDICAL OFFICER | 1,500,000 | $0 | 1,500,000 (Direct) | View |
| 2024-01-16 Exercise | 2024-01-17 4:48 pm | N/A N/A | Quince Therapeutics Inc. | QNCX | Thye Dirk CHIEF EXECUTIVE OFFICER | 149,999 | $0.94 | 1,255,302 (Direct) | View |
| 2024-01-16 Exercise | 2024-01-17 4:48 pm | N/A 2022-03-27 | Quince Therapeutics Inc. | QNCX | Thye Dirk CHIEF EXECUTIVE OFFICER | 240,530 | $0 | 1,255,302 (Direct) | View |
| 2024-01-16 Exercise | 2024-01-17 4:48 pm | N/A N/A | Quince Therapeutics Inc. | QNCX | Thye Dirk CHIEF EXECUTIVE OFFICER | 90,531 | $0.55 | 1,255,302 (Direct) | View |
| 2023-10-24 Option Award | 2023-10-26 5:54 pm | N/A 2033-10-23 | Quince Therapeutics Inc. | QNCX | Hannah Brendan Chief Business Officer and COO | 75,000 | $0 | 75,000 (Direct) | View |
| 2023-10-23 Option Award | 2023-10-24 7:46 pm | N/A 2033-10-22 | Quince Therapeutics Inc. | QNCX | Benatti Luca Director | 54,000 | $0 | 54,000 (Direct) | View |
Ownership | 2023-10-24 7:43 pm | N/A N/A | Quince Therapeutics Inc. | QNCX | Benatti Luca Director | 0 | $0 | 80,261 (Direct) | View |
| 2023-10-23 Option Award | 2023-10-24 7:42 pm | N/A 2033-10-22 | Quince Therapeutics Inc. | QNCX | Janhofer Guenter Chief Scientific Officer | 300,000 | $0 | 300,000 (Direct) | View |
Ownership | 2023-10-24 7:34 pm | N/A N/A | Quince Therapeutics Inc. | QNCX | Janhofer Guenter Chief Scientific Officer | 0 | $0 | 15,008 (Direct) | View |
| 2023-09-01 Option Award | 2023-09-06 5:43 pm | N/A 2033-08-31 | Quince Therapeutics Inc. | QNCX | Ryan Charles S. President | 545,000 | $0 | 545,000 (Direct) | View |
Ownership | 2023-09-06 5:40 pm | N/A N/A | Quince Therapeutics Inc. | QNCX | Ryan Charles S. President | 0 | $0 | 74,074 (Direct) | View |
| 2023-05-24 Option Award | 2023-05-26 5:53 pm | N/A 2033-05-23 | Quince Therapeutics Inc. | QNCX | Senner Christopher J. Director | 27,000 | $0 | 27,000 (Direct) | View |
| 2023-05-24 Option Award | 2023-05-26 5:50 pm | N/A 2033-05-23 | Quince Therapeutics Inc. | QNCX | RYAN UNA S Director | 27,000 | $0 | 27,000 (Direct) | View |
| 2023-05-24 Option Award | 2023-05-26 5:49 pm | N/A 2033-05-23 | Quince Therapeutics Inc. | QNCX | McLoughlin Margaret Director | 27,000 | $0 | 27,000 (Direct) | View |
| 2023-05-24 Option Award | 2023-05-26 5:47 pm | N/A 2033-05-23 | Quince Therapeutics Inc. | QNCX | Lamond David Director | 27,000 | $0 | 27,000 (Direct) | View |
| 2023-05-24 Option Award | 2023-05-26 5:45 pm | N/A 2033-05-23 | Quince Therapeutics Inc. | QNCX | Bray June Director | 27,000 | $0 | 27,000 (Direct) | View |
| 2023-02-01 Option Award | 2023-02-02 6:37 pm | N/A 2033-01-31 | Quince Therapeutics Inc. | QNCX | Thye Dirk Chief Executive Officer | 600,000 | $0 | 600,000 (Direct) | View |
| 2023-02-01 Option Award | 2023-02-02 6:35 pm | N/A 2033-01-31 | Quince Therapeutics Inc. | QNCX | Smith Karen L. Chief Medical Officer | 225,000 | $0 | 225,000 (Direct) | View |
| 2023-02-01 Option Award | 2023-02-02 6:32 pm | N/A 2033-01-31 | Quince Therapeutics Inc. | QNCX | Monohon Ted Chief Accounting Officer & VP | 110,000 | $0 | 110,000 (Direct) | View |
| 2023-02-01 Option Award | 2023-02-02 6:29 pm | N/A 2033-01-31 | Quince Therapeutics Inc. | QNCX | Hannah Brendan Chief Business Officer | 225,000 | $0 | 225,000 (Direct) | View |
| 2022-12-05 Tax Withholding | 2022-12-07 5:37 pm | N/A N/A | Quince Therapeutics Inc. | QNCX | Monohon Ted Chief Accounting Officer & VP | 1,640 | $0.72 | 29,311 (Direct) | View |
| 2022-09-06 Tax Withholding | 2022-09-08 5:58 pm | N/A N/A | Quince Therapeutics Inc. | QNCX | Monohon Ted Chief Accounting Officer & VP | 1,520 | $1.64 | 30,951 (Direct) | View |
| 2022-06-29 Option Award | 2022-07-01 5:03 pm | N/A 2032-06-28 | Cortexyme Inc. | CRTX | Monohon Ted Chief Accounting Officer & VP | 250,000 | $0 | 250,000 (Direct) | View |
| 2022-06-09 Option Award | 2022-06-10 4:20 pm | N/A 2032-06-08 | Cortexyme Inc. | CRTX | Bray June Director | 54,000 | $0 | 54,000 (Direct) | View |
| 2022-06-08 Option Award | 2022-06-09 8:48 pm | N/A 2032-06-07 | Cortexyme Inc. | CRTX | Senner Christopher J. Director | 27,000 | $0 | 27,000 (Direct) | View |
| 2022-06-08 Option Award | 2022-06-09 8:45 pm | N/A 2032-06-07 | Cortexyme Inc. | CRTX | RYAN UNA S Director | 27,000 | $0 | 27,000 (Direct) | View |
| 2022-06-08 Option Award | 2022-06-09 8:43 pm | N/A 2032-06-07 | Cortexyme Inc. | CRTX | Lamond David Director | 27,000 | $0 | 27,000 (Direct) | View |